Fair value measurement (Tables)

12 Months Ended

Dec. 31, 2021

Fair Value Disclosures [Abstract]

Financial Assets and Liabilities Carried at Fair Value Measured on Recurring Basis

The following tables provide information regarding our financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2021 and 2020:

	Basis of fair value measurement
	December 31, 2021		(Level 1)		(Level 2)		(Level 3)
Investments in marketable securities	$	19,186	$	19,186	$	—	$	—
Derivative assets	33,291		—		33,291		—
Derivative liabilities	1,140		—		1,140		—
Contingent consideration liabilities	9,814		—		—		9,814

	Basis of fair value measurement
	December 31, 2020		(Level 1)		(Level 2)		(Level 3)
Investments in marketable securities	$	12,617	$	12,617	$	—	$	—
Derivative assets	21,858		—		21,858		—
Derivative liabilities	35,995		—		35,995		—
Contingent consideration liabilities	36,633		—		—		36,633

There were no transfers of financial assets or liabilities into or out of Level 3 within the fair value hierarchy during the years ended December 31, 2021 or 2020.

Schedule of Valuation Techniques

The table below provides additional information regarding the valuation technique and inputs used in determining the fair value of contingent consideration.

Contingent Consideration Liability	Valuation Technique	Unobservable Input	Range (Weighted average)
Milestone-based payment
	Discounted cash flow	Discount rate	1.9% - 2.2% (2.0%)
		Projected year of payment	2022 - 2023
Revenue-based
	Discounted cash flow	Discount rate	1.7% - 10.0% (6.1%)
		Projected year of payment	2022 - 2029

Reconciliation of Changes in Level 3 Financial Liabilities Measured at Fair Value on Recurring Basis

The following table provides information regarding changes in our contingent consideration liabilities for the years ended December 31, 2021 and 2020:

	2021		2020
Beginning balance – January 1	$	36,633	$	219,908
Payments (1)	(31,678)		(146,971)
Revaluations and other adjustments	4,895		(36,714)
Translation adjustment	(36)		410
Ending balance – December 31	$	9,814	$	36,633

(1) Includes $17.4 million payment associated with a settlement reached with the shareholders from whom we acquired Essential Medical, Inc. See Note 17 for additional information related to the settlement.